Autophagy and senescence are both well-established responses to chemotherapy and radiation that often occur in parallel, contributing to growth arrest in tumor cells. However, it has not been established whether this growth arrest is reversible. This question was addressed using non-small cell lung cancer models exposed to the cancer chemotherapeutic drug, etoposide. Senescent cells that were sorted, identified by β -galactosidase staining and alterations in morphology, isolated by flow cytometric cell sorting based on C 12 FDG staining, and real-time live microscopy were found to be capable of recovering proliferative capacity. Autophagy, monitored by vacuole formation, SQSTM1/p62 degradation, and LC3BII generation did not interfere with either the senescence arrest or proliferative recovery and was nonprotective in function (i.e. autophagy inhibition via both pharmacological and genetic strategies had negligible impact on the response to etoposide).
Introduction
Autophagy and senescence are both well-established responses to cellular stress 1,2 .
Autophagy and senescence, whether induced by oncogene activation, chemotherapy or radiation often, if not always, occur in parallel, although we and others have determined that these responses are dissociable (i.e. senescence occurs and/or is sustained even when autophagy is suppressed) [3] [4] [5] .
Autophagy, which is predominantly cell survival mechanism, has been proposed to contribute to therapy resistance and potentially to tumor dormancy 1, 6 . With regard to tumor dormancy, this would require that some subset of the dormant tumor cell population could eventually escape from the dormant state. In contrast, senescence, whether a consequence of telomere shortening (replicative senescence), oncogene activation (oncogene-induced) or that which occurs in tumor cells in response to chemotherapy or radiation (therapy-induced senescence, accelerated or premature senescence) is generally considered to be irreversible [7] [8] [9] [10] .
However, it is clear that senescent cells actually retain reproductive potential since transformation and immortalization involve escape from replicative senescence [11] [12] [13] . A recent review published by our research group highlights studies of the capacity of cells to escape from the various forms of senescence 14 . With regard to therapy-induced senescence, reports by our group 15, 16 as well as other laboratories have presented evidence in support of the premise that tumor cells in a state of senescence are not obligatorily in a terminally growth-arrested state [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] .
These studies generally involved genetic manipulation of cell cycle regulators, such as p53 or p16 INK4a ; however, it has remained uncertain whether spontaneous restoration of proliferative capacity can occur from the senescent state. Furthermore, conclusions relating to the reversibility of senescence have generally been based on studies in mass culture, where the origin of the replicating cells cannot be unequivocally attributed to the senescent population.
A primary finding of the current work is the capacity of etoposide-induced highly autophagic, senescent lung cancer cells, to resume cellular division, which we have previously termed proliferative recovery 2 . Furthermore, autophagy and senescence induced by etoposide are found to be dissociable and the capacity of the cells to recover post-drug treatment is not compromised when autophagy is inhibited either pharmacologically or genetically. Finally, the autophagy is clearly non-cytoprotective in function, as we have previously shown in other experimental models 15, 27, 28 .
Based on these findings, we propose the novel premise that therapy-induced senescence is reversible and independent of autophagic cell survival. Senescence, rather than autophagy, is likely to play a critical role in determining the nature of the tumor cell response in terms of transient growth arrest, the relative lack of cell death, and the ultimate re-emergence of the tumor cells from the growth-arrested state to regain proliferative function and contribute to disease recurrence.
Results
Etoposide promotes growth arrest, autophagy and senescence in NSCLC cells followed by proliferative recovery.
H460 human NSCLC cells undergo growth arrest followed by proliferative recovery upon exposure to etoposide, a mainstay chemotherapeutic agent ( Figure 1A , left panel).
Exposure to 1 µM etoposide, the concentration utilized in all subsequent studies, resulted in growth arrest for at least five days followed by proliferative recovery at approximately 7 days post-drug exposure. A similar response pattern to etoposide was also observed in the A549 NSCLC cell line ( Figure 1A, right panel) . Recovery of H460 cells is also shown in the colony forming assay in Figure 1B . As would have been anticipated based on the fact that etoposide promoted autophagy in A549 and U1810 NSCLC cell lines 29 , autophagy was also evident in the H460 cells exposed to etoposide. 
Autophagy plays a non-cytoprotective role in response to etoposide in H460 cells and does not
interfere with the ability of cells to recover proliferative capacity.
Autophagy has historically been considered a survival response under conditions of nutrient deprivation or hypoxia, as well as a process that facilitates tumor growth and serves as a mechanism of resistance to therapy 31, 32 . To determine whether autophagy might be protecting the H460 cells against etoposide toxicity and/or facilitating recovery following the senescent growth arrest, autophagy was suppressed using both pharmacological and genetic strategies, and the impact on sensitivity to etoposide was monitored. Cells were pretreated for 3 hours with the autophagy inhibitors chloroquine (CQ, 10 µM) or bafilomycin A1 (Baf, 5 nM) followed by 24
hours of exposure to etoposide in the presence of the CQ or Baf. The presence of CQ and Baf resulted in failure of lysosomal acidification, which is reflected by the yellow staining of vacuoles by acridine orange (Figure 2A) ; autophagy inhibition was confirmed by decreased degradation of p62/SQTSM1 in the presence of CQ or Baf ( Figure 2B ). Figure 2C shows that inhibition of autophagy did not alter sensitivity to etoposide in both MTT and clonogenic survival assays (except moderately with Baf at 1 µM etoposide), indicating that the autophagy was not cytoprotective. This conclusion relating to the function of autophagy was supported by the temporal response studies presented in Figure 2D , where neither CQ nor Baf was able to alter the profile of growth arrest; furthermore, proliferative recovery occurred in the cells treated with etoposide both in the absence and presence of CQ or Baf.
Autophagy was also blocked genetically using shRNA-meditated knockdown of Atg5.
Confirmation of gene silencing is shown by immunoblotting where p62/SQTSM1 levels are increased and LC3BI to LC3BII conversion is reduced ( Figure 2E ). In previous studies of radiation-induced autophagy and senescence in HCT-116 colon carcinoma cells, we demonstrated a direct correspondence between the extent of autophagy and senescence, where both responses were related to the extent of DNA damage 15 . However, in this work as well as studies of doxorubicin-induced autophagy and senescence in breast tumor cells,
we report that the two responses are clearly dissociable 5, 15 . Our studies further demonstrate that the senescence induced by etoposide in the H460 cells is independent of autophagy, as genetic silencing of autophagy failed to influence the promotion of senescence by etoposide ( Figure   2H ).
Proliferative recovery is associated with a decline in SA-β-galactosidase activity, entry into G1
and reduction in p21 Waf1 expression. Since it is possible that the proliferating cells were not derived solely from the senescent population, cells were labeled with C 12 FDG followed by flow cytometric cell sorting and subsequent seeding of the highest C 12 FDG-stained subpopulations 15 . As shown in Figure 4B , the highly C 12 FDG-positive cells demonstrated restoration of proliferative capacity.
While the data generated in H460 mass cultures and senescence-enriched populations are consistent with TIS being reversible, we recognized that a careful lineage tracing approach is essential to distinguish between cancer cells that might have initially evaded etoposide-induced senescence from cells that had undergone TIS, but recovered proliferative potential.
Consequently, the high C 12 FDG-positive population was reseeded and monitored by live cell imaging using phase contrast microscopy. The temporal response after etoposide-induced senescence was found to be quite heterogeneous. Over the period of observation (Supplementary Videos 1, 2, and 3), the majority of the senescent cell population persisted in a growth-arrested state, while a few cells were observed to eventually surrender to stress and switch to apoptosis (or possibly mitotic catastrophe). However, occasional hypertrophic, flattened senescent cells that had remained in an arrested state were found to be capable of recovering the ability to divide ( Figure 4C ). Whether this is simply a stochastic outcome or reflective of unique characteristics of subsets in the tumor cell population, is a question that we will attempt to address in future work. Nevertheless, these studies, taken together with the data in Figure 4 , appear to establish the reversibility of chemotherapy-induced senescence.
Discussion
Although the bulk of the literature has focused on the cytoprotective function(s) of autophagy, we and others have shown that in a number of studies interference with autophagy failed to alter drug or radiation sensitivity or to promote apoptosis 15, 27, 28 , as is also the case in the current work. In the case of radiation, the non-cytoprotective function of autophagy was dependent on the cells being mutant or null in p53 27 . However, in the current work, it is clear that autophagy induced by etoposide in the H460 cells (p53 WT) is non-cytoprotective, an observation we were able to replicate with other cytotoxic agents (data not shown). These findings are consistent with a recent report by Eng et al 35 demonstrating non-cytoprotective autophagy induced by more than 30 chemotherapeutic drugs in the A549 NSCLC cell line.
Etoposide-induced non-cytoprotective autophagy did not appear to affect the profile of growth arrest and proliferative recovery, indicating that this form of autophagy is unlikely to contribute to drug sensitivity.
Studies of oncogene-induced senescence have been suggestive of a close relationship between autophagy and senescence 36, 37 . However, the relationship has not been consistent in different experimental models 38, 39 . In both this work as well as our own previous studies 4, 5, 15 , it is quite clear that autophagy and senescence are dissociable.
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On the other hand, senescence induction and resolution showed a more consistent pattern with growth arrest and recovery. Our laboratories previously reported on the promotion of senescence in response to chemotherapy and radiation, and furthermore provided evidence that therapy-induced senescence (TIS) may, in fact, be reversible [14] [15] [16] 40 . Other research groups have also published data supporting the premise that TIS may be reversible [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] . The most significant finding generated by the current work, utilizing multiple and complementary approaches, is that recovery from senescence can and does occur even from a highly β -galactosidase-active population independently of autophagy; this finding has been reproduced in breast tumor cells A number of factors may be responsible for allowing proliferative recovery to occur in this experimental system. One is the absence of functional p16 INK4a in these cells 41 . While the activation of the p53-p21 axis accompanied by the senescence-associated secretory phenotype (SASP) may be sufficient to induce senescence-associated growth arrest in response to etoposide-induced DNA damage, a sustained senescence-based growth arrest is likely to be dependent upon p16 INK4a function 24, 42 . Since inactivation or loss of p16 is quite common in cancer cells 43, 44 , reversibility of chemotherapy-induced senescence might not be an infrequent observation. The p16 INK4a -retinoblastoma protein (RB) pathway has also been shown to be pivotal to the formation of Senescence-associated Heterochromatic Foci (SAHF), which are 1 2 absent in this model (data not shown). SAHF might contribute to maintenance of the senescent phenotype 45 .
Taken together with our previous findings relating to regrowth following radiationinduced senescence, these observations, based on enrichment of senescence and real-time microscopy, support the premise that senescence induced by chemotherapy or radiation can be reversed in tumor cells and this reversal is independently of autophagy. If this proves to be the case in tumor-bearing animals, we can speculate that senescence could be the basis for some forms of tumor dormancy. That is, it is possible to imagine that after being exposed to cycles of cytotoxic chemotherapy, a few senescent cancer cells can reside in a dormant state at distant sites and eventually resume proliferation, contributing to or being responsible for disease recurrence. CQ or Baf; drugs were removed and replaced with fresh media after 24 h. Cells were incubated for 7 days, then fixed with methanol, stained with crystal violet, and counted (ColCount, Discovery Technology International).
Growth inhibition and clonogenic survival

Flow cytometry and fluorescence microscopy
All of the flow cytometry analyses were performed using BD FACSCanto II and BD FACSDiva software at the Virginia Commonwealth University Flow Cytometry Core Facility. For C 12 FDG, acridine orange, Annexin V/Propidium Iodide, γ H2AX, and cell cycle analyses, 10,000 cells per replicate within the gated region were analyzed. Three replicates for each condition were analyzed in each independent experiment. Labeling procedures, gating, and analysis followed our previously published protocols with minor adjustment for the tested cell line 5, 15, 47 .
Evaluation of senescence by β -galactosidase and C 12 FDG staining β -galactosidase labeling was performed as previously described by Dimri et al 48 and in our previous publications 5, 15, 47 . Phase contrast images were taken using an Olympus inverted microscope (20X objective, Q-Color3™ Olympus Camera; Olympus, Tokyo, Japan). The C 12 FDG staining protocol was adopted from Debacq-Chainiaux et al 30 . Cells were initially treated with Baf (100 nM) for 1 h to accomplish lysosomal alkalization, followed by incubation with C 12 FDG in complete media for 2 h at 37°C. Cells were harvested for flow cytometry and imaging (20X objective, Q-Color3™ Olympus Camera, 488 filter, Olympus, Tokyo, Japan).
Western blotting and immunofluorescence
Western blots were performed as previously described 47 . Primary antibodies were used at a 1:
cells were fixed with methanol, permeabilized with 0.1% Triton X-100, and blocked with 1% bovine serum albumin (BSA). Cells were exposed to a 1:100 dilution of p21 antibodies and incubated overnight at 4°C, followed by exposure to the secondary antibody for 1 h at room temperature. After incubation, cells were mounted with DAPI and imaging was performed with an Olympus inverted microscope (20X objective, Q-Color3™ Olympus Camera, 555 filter and UV light, Olympus, Tokyo, Japan). 
Promotion of apoptosis by
Cell Cycle Distribution by Propidium iodide (PI)
Cells were harvested with 0.1% trypsin and neutralized with medium. After centrifugation, the cells were washed with PBS, then resuspended in a PI solution [50 μ g/ml PI, 4 mM sodium citrate, 0.2 mg/ml DNase-free RNase A, and 0.1% Triton-X 100] for 1 h at room temperature, while being protected from light. Before analysis, NaCl was added to the cell suspensions to 
